CHRISANTHY ORY: Open Payments
NPI 1821758806 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$454 in 22 payments from 11 companies in 2025. Trend: 2023 $258 · 2024 $517 · 2025 $454
Food & beverage: $454
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 5 | $101 |
| SANOFI-AVENTIS U.S. LLC | 2 | $74 |
| Phathom Pharmaceuticals, Inc. | 3 | $51 |
| Lilly USA, LLC | 3 | $47 |
| Novo Nordisk Inc | 2 | $44 |
| AstraZeneca Pharmaceuticals LP | 2 | $35 |
| Otsuka America Pharmaceutical, Inc. | 1 | $28 |
| Dexcom, Inc. | 1 | $21 |
| Amgen Inc. | 1 | $19 |
| Renalytix AI, Inc. | 1 | $17 |
Products named: TZIELD, ELIQUIS, VOQUEZNA, MOUNJARO, REXULTI, Ozempic, PAXLOVID, Dexcom G6 Transmitter.
Industry payments across TX — which companies pay providers there.
